Information about Summons to Extraordinary General Meeting of Diamyd Medical
STOCKHOLM -- February 11, 2013
The following summons to an Extraordinary General Meeting of Diamyd Medical AB
will be available at Diamyd Medical’s website www.diamyd.com from Wednesday
February 13, 2013.
Summons to Extraordinary General Meeting of Diamyd Medical AB
The shareholders of Diamyd Medical AB (publ) are hereby summoned to the an
Extra General Meeting on Wednesday March 13, 2013 at 2.00 pm in Garnisonen
Konferens, Karlavägen 100 in Stockholm, Sweden.
Shareholders who wish to attend the meeting must be recorded in the register
of shareholders held by Euroclear Sweden AB by Thursday March 7, 2013, and
must also notify the Company of their intention to attend the Meeting by mail
to Diamyd Medical, Karlavägen 108, SE-115 26 Stockholm, by e-mail to
email@example.com or on the Company’s website, www.diamyd.com not
later than Thursday
March 7, 2013. The notification must state the shareholder’s name, address,
telephone number, personal identity number or company registration number,
registered shareholding and the name of any shareholder’s representative.
Shareholders whose shares are registered in custodial accounts must ask the
custodian to temporarily register the shares in the shareholder’s name
(registration of entitlement to vote) to obtain the right to participate in
the Extraordinary General meeting. The shares must be registered not later
than March 7, 2013.
1. Opening of the Meeting.
2. Election of Chairman.
3. Establishment and approval of the register of voters.
4. Approval of the agenda.
5. Election of one or two persons to certify the minutes.
6. Verification of whether the Extraordinary General Meeting has been duly
7. Proposals from the shareholders:
a) that election of a new Board be held;
b) that new Articles of Association be adopted, with a sole amendment being to
paragraph 1, that the Company’s new firm-name be Diamyd Sverige AB (publ);
c) that Diamyd Medical AB’s Board of Directors be instructed to establish a
wholly owned subsidiary, with the same number of shares as Diamyd Medical AB
and with only one class of shares, and that all of the Company’s share
holdings and approximately SEK 40,000 000 in cash to be transferred to this
d) that Diamyd Medical AB enter into liquidation with effect from the day of
the Extraordinary General Meeting.
8. Close of Meeting.
Proposals from shareholders:
A group of shareholders (herein referred to as “the Shareholders”) has
submitted a proposal to the Board of Directors of Diamyd Medical AB (herein
referred to as “Diamyd”) in writing, dated February 8, 2013, that the Board of
Directors of Diamyd convene an extraordinary meeting to handle the issues
presented in item 7 of the above proposal for the agenda.
The Shareholders claim to represent 8,883,351 Series B shares in Diamyd,
corresponding to about 21 percent of the votes and 30 percent of the total
number of shares in Diamyd.
The Shareholders’ letter to Diamyd, including the Shareholder’s full proposal
regarding liquidation and the list of Shareholders is available from Diamyd
and Diamyd’s website, www.diamyd.com.
In accordance with chapter 25 section 4 of the Swedish Companies Act, Diamyd’s
Board of directors will formulate a statement concerning events of
considerable importance to Diamyd’s position, which may occur after the issue
of its Annual Report. This statement, together with the opinion of Diamyd’s
auditors of the statement, will be available from Diamyd and Diamyd’s website
as of February 20, 2013.
All documents will be sent free of charge to shareholders who request them and
provide their postal address.
At the time of the summons, there are 29,597,133 shares, made up of 1,437,876
shares of Series A (1 vote) and
28,141,257 shares of Series B (1/10 of a vote). There are a total of
Stockholm, February 11, 2013
Diamyd Medical AB (publ)
The Board of Directors
About Diamyd Medical Diamyd Medical was founded in 1996 and is active in the
field of pharmaceutical development. Diamyd Medical is headquartered in
Stockholm, Sweden. The Company’s development project consists of the protein
GAD for the treatment and prevention of autoimmune diabetes. A Swedish
researcher-initiated Phase II study is ongoing to evaluate whether GAD can
prevent type 1 diabetes in children who are at high risk of developing the
Diamyd Medical also has holdings in the gene therapy company Periphagen
Holdings, Inc. (USA), the vaccine company Protein Sciences Corporation (USA)
and the diagnostics company Mercodia AB (Sweden).
Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm
(ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the
Pink OTC Markets and the Bank of New York Mellon (PAL). Further information is
available on the Company’s website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities
Markets Act, the Swedish Financial Instruments Trading Act, or the
requirements stated in the listing agreements.
Diamyd Medical AB (publ) Karlavägen 108, SE-115 26 Stockholm, Sweden. Phone:
+46 8 661 00 26, Fax: +46 8 661 63 68 E-mail: firstname.lastname@example.org. Reg. no:
This information was brought to you by Cision http://www.cisionwire.com
Anders Essen-Möller, 070-551 0679
Chairman Diamyd Medical AB
Press spacebar to pause and continue. Press esc to stop.